Eli Lilly has filed more lawsuits to halt sales of counterfeit Mounjaro, Reuters’ Bhanvi Satija reports. In its six separate lawsuits filed in the courts of Ohio, Texas, Hawaii and the District of Columbia, Lilly has alleged that these entities, which include medical spas and wellness centers, are falsely claiming that their compounded versions of tirzepatide, the active ingredient in Mounjaro, are approved by the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Notches Up on Pursuit of Bogus Mounjaro
- Insider Trade: Lilly Endowment Sells Eli Lilly Shares Worth $172M
- Growing Demand for GLP-1 Puts Eli Lilly (NYSE:LLY) in Prime Position
- Eli Lilly works to develop more potent anti-obesity treatment, WSJ reports
- FDA grants traditional approval to Lilly’s Retevmo for thyroid cancer